| Code | CSB-RA015057MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Apitegromab, targeting myostatin (MSTN), a negative regulator of skeletal muscle growth and development. Myostatin, a member of the transforming growth factor-beta superfamily, functions as a potent inhibitor of muscle mass by suppressing myoblast proliferation and differentiation. Elevated myostatin activity is associated with muscle wasting conditions including muscular dystrophies, sarcopenia, and cachexia, while genetic myostatin deficiency results in enhanced muscle hypertrophy. Dysregulated myostatin signaling has also been implicated in metabolic disorders and age-related muscle decline.
Apitegromab is a fully humanizedized monoclonal antibody designed to selectively inhibit myostatin activation by binding to the latent form of the protein, preventing its proteolytic activation and subsequent signaling through activin receptors. This biosimilar antibody provides researchers with a valuable tool for investigating myostatin biology, exploring muscle regeneration mechanisms, and studying therapeutic strategies for neuromuscular diseases and metabolic conditions. It supports investigations into muscle homeostasis, protein degradation pathways, and potential interventions for muscle-wasting disorders.
There are currently no reviews for this product.